Chemotherapy in Alveolar Echinococcosis of Multi-organs: What's the Role?

Overview

Journal Parasitol Res

Specialty Parasitology

Date 2013 Mar 20

PMID 23508760

Citations 8

Authors

Haitao Li

Tao Song

Yingmei Shao

Aili Tuergan

Bo Ran

Hao Wen

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the clinical efficiency of chemotherapy for the treatment of human alveolar echinococcosis (AE). Twenty-four patients who suffered from late-stage AE were enrolled in this study. The classification of the disease stages was performed according to the PNM (parasite lesion, neighboring organ invasion, metastases) classification system established by the World Health Organization Informal Working Group on Echinococcosis and classification standards. Radical surgery (n = 3), palliative surgery plus chemotherapy (n = 11), and sole chemotherapy (n = 10) were given, respectively. For those with AE metastasis with spleen and kidney, radical surgery was effective for the treatment. However, the treatment efficiency for those with AE metastasis to bone tissues was unfavorable. Significant improvement was noted in those with cerebral lesions after chemotherapy. Stable health conditions were observed in those with pulmonary lesions after chemotherapy. For those with liver lesion, long stable health conditions were noted after chemotherapy. However, surgical interventions were needed as the occurrence of bile duct complications. With regards to the other lesions, radical surgeries were recommended. Satisfactory treatment outcomes were obtained in those with AE after chemotherapy.

Citing Articles

Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis.

Qin M, Yang G, Yan J, Wang L, Feng Y, Wang D Infect Dis Poverty. 2024; 13(1):98.

PMID: 39707489 PMC: 11662814. DOI: 10.1186/s40249-024-01268-3.

Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis.

Li J, Yang Y, Han X, Li J, Tian M, Qi W Int J Nanomedicine. 2023; 18:3069-3085.

PMID: 37312930 PMC: 10259527. DOI: 10.2147/IJN.S397526.

Therapeutic efficacy of nanocompounds in the treatment of cystic and alveolar echinococcoses: challenges and future prospects.

Bakhtiar N, Akbarzadeh A, Casulli A, Mahami-Oskouei M, Ahmadpour E, Nami S Parasitol Res. 2019; 118(9):2455-2466.

PMID: 31402401 DOI: 10.1007/s00436-019-06416-5.

Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Siles-Lucas M, Casulli A, Cirilli R, Carmena D PLoS Negl Trop Dis. 2018; 12(4):e0006422.

PMID: 29677189 PMC: 5931691. DOI: 10.1371/journal.pntd.0006422.

Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis: A Non-Randomized Clinical Trial.

Li H, Song T, Shao Y, Aili T, Ahan A, Wen H Medicine (Baltimore). 2016; 95(4):e2237.

PMID: 26825878 PMC: 5291548. DOI: 10.1097/MD.0000000000002237.

References

Vuitton D, Zhou H, Bresson-Hadni S, Wang Q, Piarroux M, Raoul F . Epidemiology of alveolar echinococcosis with particular reference to China and Europe. Parasitology. 2004; 127 Suppl:S87-107. View

Horton J . Albendazole for the treatment of echinococcosis. Fundam Clin Pharmacol. 2003; 17(2):205-12. DOI: 10.1046/j.1472-8206.2003.00171.x. View

Moro P, Schantz P . Echinococcosis: a review. Int J Infect Dis. 2008; 13(2):125-33. DOI: 10.1016/j.ijid.2008.03.037. View

Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P . Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother. 2000; 46(3):451-6. DOI: 10.1093/jac/46.3.451. View

Kern P, Wen H, Sato N, Vuitton D, Gruener B, Shao Y . WHO classification of alveolar echinococcosis: principles and application. Parasitol Int. 2005; 55 Suppl:S283-7. DOI: 10.1016/j.parint.2005.11.041. View

Jiang C . Two cases of liver alveolar echinococcosis associated with simultaneous lung and brain metastases. Chin Med J (Engl). 2003; 115(12):1898-901. View

Rubini-Campagna A, Kermarrec E, Laurent V, Regent D . [Hepatic and extrahepatic alveolar echinococcosis: CT and MR imaging features]. J Radiol. 2008; 89(6):765-74. DOI: 10.1016/s0221-0363(08)73782-x. View

Li H, Tuerganaili , Ayifuhanahan , Shao Y, Zhao J, Ran B . [Clinical experiences in the treatment of human multi-organ alveolar echinococcosis by surgery and drugs]. Zhonghua Yi Xue Za Zhi. 2010; 90(40):2839-42. View

McManus D, Zhang W, Li J, Bartley P . Echinococcosis. Lancet. 2003; 362(9392):1295-304. DOI: 10.1016/S0140-6736(03)14573-4. View

10.

Kern P, Bardonnet K, Renner E, Auer H, Pawlowski Z, Ammann R . European echinococcosis registry: human alveolar echinococcosis, Europe, 1982-2000. Emerg Infect Dis. 2003; 9(3):343-9. PMC: 2958541. DOI: 10.3201/eid0903.020341. View

11.

Coskun A, Ozturk M, Karahan O, Erdogan N, Isin S, Gulec M . Alveolar echinococcosis of the liver: correlative color Doppler US, CT, and MRI study. Acta Radiol. 2004; 45(5):492-8. DOI: 10.1080/02841850410005912. View

12.

Wilson J, Davidson M, RAUSCH R . A clinical trial of mebendazole in the treatment of alveolar hydatid disease. Am Rev Respir Dis. 1978; 118(4):747-57. DOI: 10.1164/arrd.1978.118.4.747. View

13.

Bottcher D, Bangoura B, Schmaschke R, Muller K, Fischer S, Vobis V . Diagnostics and epidemiology of alveolar echinococcosis in slaughtered pigs from large-scale husbandries in Germany. Parasitol Res. 2012; 112(2):629-36. DOI: 10.1007/s00436-012-3177-2. View

14.

Brunetti E, Kern P, Vuitton D . Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2009; 114(1):1-16. DOI: 10.1016/j.actatropica.2009.11.001. View

15.

Hemphill A, Muller J . Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options. J Helminthol. 2009; 83(2):99-111. DOI: 10.1017/S0022149X0928936X. View

16.

Yamano K, Kanetoshi A, Goto A, Kishimoto M, Kobayashi N, Fujimoto S . Japanese monkey (Macaca fuscata) with alveolar echinococcosis after treatment with albendazole for 10 years: serodiagnosis and determination of albendazole metabolites. Parasitol Res. 2009; 106(1):69-74. DOI: 10.1007/s00436-009-1627-2. View

17.

Wilson J, RAUSCH R, Wilson F . Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos. Ann Surg. 1995; 221(3):315-23. PMC: 1234575. DOI: 10.1097/00000658-199503000-00015. View

18.

Reuter S, Buck A, Manfras B, Kratzer W, Seitz H, Darge K . Structured treatment interruption in patients with alveolar echinococcosis. Hepatology. 2004; 39(2):509-17. DOI: 10.1002/hep.20078. View

19.

Eckert J, Deplazes P . Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev. 2004; 17(1):107-35. PMC: 321468. DOI: 10.1128/CMR.17.1.107-135.2004. View

20.

Liu Y, Wang X, Song Gao J, Qingyao Y, Horton J . Continuous albendazole therapy in alveolar echinococcosis: long-term follow-up observation of 20 cases. Trans R Soc Trop Med Hyg. 2009; 103(8):768-78. DOI: 10.1016/j.trstmh.2009.04.006. View